RecruitingPhase 2NCT06189820

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases


Sponsor

Erasme University Hospital

Enrollment

70 participants

Start Date

Mar 9, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines

Exclusion Criteria3

  • Pregnant or nursing patients
  • Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
  • Patients with an active lung neoplasm or any active neoplasm for blood samples

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFAPI PET/CT

In the department of Nuclear Medicine: * Installation in a relax chair after weight and height control * Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started. * Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46


Locations(1)

Medecine

Brussels, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06189820


Related Trials